Stock A298060 SCM LIFESCIENCE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News SCM Lifescience Co., Ltd.

Equities

A298060

KR7298060005

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-28 EDT 		5-day change 1st Jan Change
2,825 KRW -2.75% Intraday chart for SCM Lifescience Co., Ltd. -5.83% -25.26%
2023 SCM Lifescience Co., Ltd.(KOSDAQ:A298060) dropped from S&P Global BMI Index CI
2023 SCM LifeScience to Raise 30.9 Billion Won via Share Issuance MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others
AQ
SCM Lifescience Co., Ltd.(KOSDAQ:A298060) dropped from S&P Global BMI Index
CI
Graft Versus Host Disease Pipeline, Clinical Trials, and Key Companies|Biocon, Medac GmbH, MaaT Pharma, , Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience
AQ
SCM LifeScience to Raise 30.9 Billion Won via Share Issuance
MT
Scm Lifescience Co., Ltd. Appoints Song Sun-Uk as CEO
CI
Vita Therapeutics, Inc. announced that it has received $32 million in funding from Cambrian BioPharma, Inc., SCM Lifescience Co., Ltd., Early Light Ventures
CI
Vita Therapeutics, Inc. announced that it expects to receive $22.443036 million in funding
CI
SCM Lifescience Co., Ltd.(KOSDAQ:A298060) added to S&P Global BMI Index
CI
SCM Lifescience Co., Ltd. has completed an IPO in the amount of KRW 30.6 billion.
CI
SCM Lifescience Co., Ltd. has filed an IPO.
CI
Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.
CI
Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.
CI
SCM LIFESCIENCE Co., Ltd. announced that it has received KRW 5.5000032 billion in funding from Duopharma Biotech Berhad
CI
SCM LIFESCIENCE Co., Ltd. announced that it expects to receive KRW 5.5000032 billion in funding from CCM Duopharma Biotech Berhad
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A298060 Stock
  4. News SCM Lifescience Co., Ltd.